Cholinergic Status and the Metabolic Syndrome

NCT ID: NCT01332708

Last Updated: 2011-04-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aims in the current study are to examine whether the cholinergic status should be considered as another risk factor for the metabolic syndrome and it's co-morbidities and to test the effect of a hypocaloric high complex carbohydrates diet on the cholinergic status of overweight and obese adults with and without the metabolic syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Intervention studies have demonstrated that the autonomic disturbances of the metabolic syndrome may be reversible. A reduction in body weight induced by a hypocaloric diet exerts a marked reduction in sympathetic activity in obese people with or without metabolic syndrome. Incorporation of regular, moderate intensity aerobic exercise training during a dietary weight loss program does not confer additional benefits on resting sympathetic neural activity, compared with weight loss by diet alone. A new method has been developed to examine the sympathetic-parasympathetic status of an individual - the cholinergic status. Cholinergic Status represents the total soluble circulation capacity for acetylcholine hydrolysis. Higher cholinergic status means the individual is more sympathetic .

A cross sectional study that took place in Tel Aviv Sorasky medical center and included 632 participants found that the cholinergic status is related to metabolic syndrome parameters in a dose response manner and that it correlates significantly with glucose,HbA1c, lipid profile and hs-CRP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese and overweight subjects

The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.

Group Type EXPERIMENTAL

high complex carbohydrates diet given in a diet group

Intervention Type BEHAVIORAL

diet groups that meet every week for eight weeks or more.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

high complex carbohydrates diet given in a diet group

diet groups that meet every week for eight weeks or more.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI ≥ 25kg/m2
* Stable weight (±1kg)in the previous six months
* Non smokers

Exclusion Criteria

* Type II diabetes
* Hypertension pharmacologically treated
* Cardiovascular disease
* Renal disease
* Cirrhosis and end-stage liver failure
* Thyroid disease
* Cerebrovascular disease
* Cancer
* Autoimmune disease
* Chronic inflammatory disease
* Surgery or heart catheterization in the previous six months
* Use of drugs known to affect measured parameters
Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tel-Aviv Sourasky Medical Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TASMC-11-SB-10-538-CTIL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Processing and Effects of Cannabis
NCT00225407 UNKNOWN PHASE1